[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"news-5---":3,"news-meta":862},{"data":4,"pagination":857},[5,43,81,118,157,217,266,322,379,438,494,545,589,632,684,728,765,811],{"_id":6,"slug":7,"articleType":8,"body":9,"createdAt":13,"dek":14,"entities":15,"headline":22,"imageAlt":23,"imageUrl":24,"keyFacts":25,"language":33,"publishedAt":34,"seo":35,"sources":37,"summary":41,"updatedAt":42},"6a91662faeddfad21a39f9f4","diversity-is-not-the-same-as-equity-in-us-cannabis-industry-5e77231c","other",[10,11,12],"A commentary published by MJBizDaily contends that diversity and equity are distinct concepts in the US cannabis industry, warning against treating them as synonymous.","The piece argues that meaningful equity requires repair to follow harm, rather than relying on diversity metrics alone.","It further states that power must include the people who built the road to legalization, pointing to the need for structural inclusion of communities most affected by cannabis prohibition.","2026-08-28T10:42:55.140Z","Commentary argues that repair must follow harm and power must include the people who built the road to legalization.",{"brands":16,"products":17,"markets":18,"organizations":20},[],[],[19],"US",[21],"MJBizDaily","Diversity is not the same as equity in US cannabis industry","MJBizDaily commentary on diversity and equity in the US cannabis industry.","",[26,30],{"claim":27,"sourceUrl":28,"_id":29},"Diversity is not the same as equity in the US cannabis industry.","https:\u002F\u002Fmjbizdaily.com\u002Fnews\u002Fdiversity-is-not-the-same-as-equity-in-us-cannabis-industry\u002F617799\u002F","6a91662f0385656fb2e2094c",{"claim":31,"sourceUrl":28,"_id":32},"Repair must follow harm, and power must include the people who built the road to legalization.","6a91662f0385656fb2e2094d","en","2026-08-28T10:42:56.554Z",{"title":22,"description":36},"Commentary argues that repair must follow harm and power must include the people who built the road to legalization in the US cannabis industry.",[38],{"name":21,"url":28,"trustTier":39,"_id":40},"trade","6a91662f0385656fb2e2094b","A new commentary from MJBizDaily argues that diversity and equity are not interchangeable in the US cannabis industry, emphasizing that repair must follow harm and that power must include the people who built the road to legalization.","2026-08-28T10:42:56.557Z",{"_id":44,"slug":45,"articleType":46,"body":47,"createdAt":51,"dek":52,"entities":53,"headline":59,"imageAlt":60,"imageUrl":24,"keyFacts":61,"language":33,"publishedAt":72,"seo":73,"sources":76,"summary":79,"updatedAt":80},"6a90966faeddfad21a39f9ca","connecticut-cannabis-sales-stay-flat-while-tax-revenue-jumps-67-d2a23d46","market",[48,49,50],"Connecticut's cannabis market showed nearly flat sales while tax revenue collected by the state jumped 67%.","The gap is being driven by Connecticut's THC potency tax, according to MJBizDaily, which is scheduled to end on Oct. 1.","The data points to a market where top-line sales changes are not directly tracking revenue collected by the state.","2026-08-27T19:56:31.817Z","The gap stems from the state's THC potency tax, which is scheduled to end on Oct. 1.",{"brands":54,"products":55,"markets":56,"organizations":58},[],[],[57],"Connecticut",[],"Connecticut Cannabis Sales Stay Flat While Tax Revenue Jumps 67%","Connecticut cannabis tax revenue chart showing flat sales and rising tax collections",[62,66,69],{"claim":63,"sourceUrl":64,"_id":65},"Connecticut's cannabis tax revenue jumped 67% while sales stayed nearly flat.","https:\u002F\u002Fmjbizdaily.com\u002Fnews\u002Fconnecticut-cannabis-sales-flat-but-state-collected-more-taxes-what-happened\u002F617460\u002F","6a90966fe81f0249cd72cea9",{"claim":67,"sourceUrl":64,"_id":68},"The state's THC potency tax drove the gap.","6a90966fe81f0249cd72ceaa",{"claim":70,"sourceUrl":64,"_id":71},"Connecticut's THC potency tax ends on Oct. 1.","6a90966fe81f0249cd72ceab","2026-08-28T05:26:14.544Z",{"title":74,"description":75},"Connecticut Cannabis Sales Flat, Tax Revenue Up","Connecticut's cannabis tax revenue jumped 67% while sales stayed nearly flat due to the THC potency tax.",[77],{"name":21,"url":64,"trustTier":39,"_id":78},"6a90966fe81f0249cd72cea8","Connecticut's cannabis market saw nearly flat sales but a 67% jump in tax revenue, driven by the state's THC potency tax, which ends Oct. 1.","2026-08-28T05:26:14.557Z",{"_id":82,"slug":83,"articleType":46,"body":84,"createdAt":89,"dek":90,"entities":91,"headline":97,"imageAlt":98,"imageUrl":24,"keyFacts":99,"language":33,"publishedAt":72,"seo":110,"sources":113,"summary":116,"updatedAt":117},"6a9096aeaeddfad21a39f9cd","ohio-cannabis-sales-climb-to-684-6-million-on-pace-for-new-annual-record-e2b45389",[85,86,87,88],"Ohio's regulated cannabis market is tracking toward a record-breaking year, with combined medical and adult-use sales reaching $684.6 million through July 11, according to MJBizDaily.","The sales total includes 150.3 million units of marijuana sold across the state's licensed retailers during the period.","The pace of sales suggests Ohio is on track to surpass its previous annual cannabis sales record, reflecting continued demand in the state's expanding legal market.","The figures cover both the medical cannabis program and the newer adult-use market, which has contributed to the overall growth in transaction volume and revenue.","2026-08-27T19:57:34.884Z","Combined medical and adult-use purchases through July 11 put the state on track to surpass its previous yearly sales high.",{"brands":92,"products":93,"markets":94,"organizations":96},[],[],[95],"Ohio",[21],"Ohio cannabis sales climb to $684.6 million, on pace for new annual record","Ohio cannabis sales data showing $684.6 million in combined medical and adult-use purchases through July 11.",[100,104,107],{"claim":101,"sourceUrl":102,"_id":103},"Ohio medical and adult-use cannabis sales reached $684.6 million through July 11.","https:\u002F\u002Fmjbizdaily.com\u002Fnews\u002Fohio-cannabis-sales-increase-on-pace-to-set-new-annual-record\u002F617420\u002F","6a9096aee81f0249cd72cf7b",{"claim":105,"sourceUrl":102,"_id":106},"150.3 million units of marijuana were sold in Ohio through July 11.","6a9096aee81f0249cd72cf7c",{"claim":108,"sourceUrl":102,"_id":109},"Ohio cannabis sales are on pace to set a new annual record.","6a9096aee81f0249cd72cf7d",{"title":111,"description":112},"Ohio cannabis sales hit $684.6M, on pace for record","Ohio medical and adult-use cannabis sales reached $684.6 million through July 11, with 150.3 million units sold, putting the state on track for a new annual record.",[114],{"name":21,"url":102,"trustTier":39,"_id":115},"6a9096aee81f0249cd72cf7a","Ohio's regulated cannabis market reached $684.6 million in combined medical and adult-use sales through July 11, with 150.3 million units sold, positioning the state to set a new annual record.","2026-08-28T05:26:14.590Z",{"_id":119,"slug":120,"articleType":121,"body":122,"createdAt":127,"dek":128,"entities":129,"headline":136,"imageAlt":137,"imageUrl":24,"keyFacts":138,"language":33,"publishedAt":72,"seo":149,"sources":152,"summary":155,"updatedAt":156},"6a9096ecaeddfad21a39f9cf","illinois-opens-medical-cannabis-permit-applications-to-adult-use-retailers-baf83631","regulation",[123,124,125,126],"Illinois has created a new licensing pathway that allows adult-use cannabis retailers to apply for medical cannabis permits, according to a report from MJBizDaily. The change could reshape how some operators are regulated in the state.","Holding a medical license changes an operator's regulatory status and makes them eligible to register with the U.S. Drug Enforcement Administration, the report states. That registration status is not available to businesses that hold only adult-use licenses.","The shift may also carry financial implications. The report notes that possible tax benefits could follow for retailers that obtain medical permits, though it does not specify which federal or state tax provisions might apply.","The development comes as cannabis businesses continue to navigate a patchwork of state and federal rules. Illinois operators that pursue the new permits would be adding a medical designation to their existing adult-use operations.","2026-08-27T19:58:36.925Z","A new regulatory pathway could let existing adult-use stores register with the DEA and unlock federal tax benefits.",{"brands":130,"products":131,"markets":132,"organizations":134},[],[],[133],"Illinois",[135],"DEA","Illinois Opens Medical Cannabis Permit Applications to Adult-Use Retailers","A cannabis retail storefront in Illinois with a medical permit application document in the foreground.",[139,143,146],{"claim":140,"sourceUrl":141,"_id":142},"Illinois adult-use cannabis retailers can apply for medical permits.","https:\u002F\u002Fmjbizdaily.com\u002Fnews\u002Fillinois-adult-use-cannabis-retailers-can-apply-for-medical-permits-with-dea-and-tax-benefits-possible\u002F617401\u002F","6a9096ece81f0249cd72d048",{"claim":144,"sourceUrl":141,"_id":145},"Holding a medical license changes an operator's regulatory status and makes them eligible to register with the DEA.","6a9096ece81f0249cd72d049",{"claim":147,"sourceUrl":141,"_id":148},"Tax benefits are possible for retailers that obtain medical permits.","6a9096ece81f0249cd72d04a",{"title":150,"description":151},"Illinois Adult-Use Cannabis Retailers Can Seek Medical Permits","Illinois adult-use cannabis retailers can now apply for medical permits, potentially gaining DEA registration eligibility and tax benefits.",[153],{"name":21,"url":141,"trustTier":39,"_id":154},"6a9096ece81f0249cd72d047","Illinois adult-use cannabis retailers can now apply for medical permits, a change that alters their regulatory status and may make them eligible to register with the DEA while opening the door to possible tax benefits.","2026-08-28T05:26:14.599Z",{"_id":158,"slug":159,"articleType":46,"body":160,"createdAt":167,"dek":168,"entities":169,"headline":187,"imageAlt":188,"imageUrl":24,"keyFacts":189,"language":33,"publishedAt":72,"seo":209,"sources":212,"summary":215,"updatedAt":216},"6a909714aeddfad21a39f9d1","remexian-reports-49-volume-growth-one-year-after-high-tide-acquisition-d59ed3cb",[161,162,163,164,165,166],"Remexian Pharma GmbH, based near Berlin, distributed 7.6 tonnes of medical cannabis into the German market during High Tide's second fiscal quarter of 2026, ending April 30, marking a 49% increase compared to the same period last year. This performance generated revenues of $31.6 million, up from $25 million in the first quarter of 2026.","The growth comes one year after Canadian cannabis company High Tide acquired a 51% stake in Remexian. Stefan Adomeit, co-founder and managing director, said the partnership has been positive despite initial reservations. \"We had some reservations when a huge Canadian company approached us to buy us because we are small. We still are around 35 employees, and High Tide has 2,000 employees, much bigger, and we had our reservations. But so far we are happy, I must say. We work closely,\" Adomeit said.","Remexian supplies around 100,000 of Germany's 800,000 medical cannabis flower patients. At the start of August 2026, reimbursements for cannabis flowers through the state health-insurance programme were halted as part of a government cost-cutting drive and a preference for finished pharmaceutical products. Adomeit expressed empathy for the approximately 65,000 reimbursed patients impacted, saying, \"There's a lot of confusion, and patients are asking themselves, 'Can I actually afford to treat myself with that product or not?' Because they lost their reimbursement for flowers, and that's a sad situation.\"","However, Adomeit said the impact on Remexian's business is limited because the company focuses on self-paying patients with affordable flower. \"For our business, we are selling low-price flower, affordable flower, so our main focus are the self-paying patients, not reimbursed patients. We don't see a huge effect on our business,\" he said.","Remexian imports from 22 countries, with Canada as the primary supplier, followed by Portugal and South Africa. The company competes with about 80 companies in the German market, where pharmacy medical cannabis is priced at around €5 per gram, substantially lower than black market flower ranging from €8 to €10. The main indications for its products are pain and sleep.","Looking ahead, Adomeit remains cautious about the price-intense market. \"We are in a very price-intense market right now (with) a lot of imports, so selling prices have gone down a lot. But, so far, we are doing fine,\" he said. He also commented on the trend toward finished pharmaceutical products, such as Vertanical's upcoming oral extract for lower back pain, saying he doubts it will be a substitute for flower due to different onset times, but believes such products will take more market share over time.","2026-08-27T19:59:16.807Z","German wholesaler Remexian distributed 7.6 tonnes of medical cannabis in Q2 2026, up 49% year-over-year, despite recent reimbursement changes for flower.",{"brands":170,"products":174,"markets":177,"organizations":184},[171,172,173],"Remexian","High Tide","Vertanical",[175,176],"medical cannabis flower","oral extract",[178,179,180,181,182,183],"Germany","Canada","Portugal","South Africa","France","Spain",[185,172,186],"Remexian Pharma GmbH","Business of Cannabis","Remexian Reports 49% Volume Growth One Year After High Tide Acquisition","Remexian medical cannabis products on display, representing the company's growth in the German market.",[190,194,197,200,203,206],{"claim":191,"sourceUrl":192,"_id":193},"Remexian distributed 7.6 tonnes of medical cannabis into the German market in Q2 2026, a 49% increase year-over-year.","https:\u002F\u002Fbusinessofcannabis.com\u002Fremexian-surging-ahead-one-year-on-from-high-tide-purchase\u002F","6a909714e81f0249cd72d0ec",{"claim":195,"sourceUrl":192,"_id":196},"Remexian generated revenues of $31.6 million in Q2 2026, up from $25 million in Q1 2026.","6a909714e81f0249cd72d0ed",{"claim":198,"sourceUrl":192,"_id":199},"High Tide acquired a 51% stake in Remexian one year ago.","6a909714e81f0249cd72d0ee",{"claim":201,"sourceUrl":192,"_id":202},"Reimbursements for cannabis flowers through German state health insurance were halted at the start of August 2026.","6a909714e81f0249cd72d0ef",{"claim":204,"sourceUrl":192,"_id":205},"Remexian supplies around 100,000 of Germany's 800,000 medical cannabis flower patients.","6a909714e81f0249cd72d0f0",{"claim":207,"sourceUrl":192,"_id":208},"Remexian imports from 22 countries, with Canada as the primary supplier, followed by Portugal and South Africa.","6a909714e81f0249cd72d0f1",{"title":210,"description":211},"Remexian Reports 49% Volume Growth After High Tide Deal","German wholesaler Remexian distributed 7.6 tonnes of medical cannabis in Q2 2026, up 49% year-over-year, despite reimbursement changes for flower.",[213],{"name":186,"url":192,"trustTier":39,"_id":214},"6a909714e81f0249cd72d0eb","Remexian Pharma GmbH, Germany's leading medical cannabis wholesaler, reported a 49% year-over-year increase in distributed volume to 7.6 tonnes in the second fiscal quarter of 2026, one year after Canadian cannabis giant High Tide acquired a 51% stake. Managing Director Stefan Adomeit expressed empathy for patients affected by the halt in flower reimbursements but said the impact on Remexian is limited because its focus is on self-paying patients. The company generated $31.6 million in revenue during the quarter, up from $25 million in Q1 2026.","2026-08-28T05:26:14.609Z",{"_id":218,"slug":219,"articleType":121,"body":220,"createdAt":227,"dek":228,"entities":229,"headline":239,"imageAlt":240,"imageUrl":24,"keyFacts":241,"language":33,"publishedAt":72,"seo":258,"sources":261,"summary":264,"updatedAt":265},"6a9097bbaeddfad21a39f9d2","germany-s-new-cannabis-medicine-exilby-launches-amid-reimbursement-shake-up-3df6483a",[221,222,223,224,225,226],"The imminent launch of Exilby, an oral cannabis extract developed by German company Vertanical for chronic lower back pain, comes just days after dried cannabis flowers were removed from Germany's national health reimbursement programme under BStabG regulations. This timing gives the new pharmaceutical a significant regulatory advantage in its domestic market, according to the Branchenverband Cannabiswirtschaft (BvCW), which represents Germany's cannabis businesses.","Michael Greif, Managing Director of the BvCW, said the new rules create an artificial market protection for finished pharmaceuticals like Exilby while systematically disadvantaging extemporaneous preparations, also known as specials. He noted that finished cannabis pharmaceuticals such as Sativex typically cost around €350 or more per standard pack, leading to monthly treatment costs between $350 and $1,000-plus depending on dosage.","An estimated 800,000 patients secure medical cannabis in Germany, with most being self-payers. Around 250,000 successfully obtain statutory health insurance (GKV) reimbursement, and of those, about 65,000 were on cannabis flowers—the group that lost coverage on 30 July 2026. Benchmark medical flower prices range from €4 to €6.50 per gram, meaning a typical patient using 20g to 30g per month pays up to €180, cheaper than cannabis clubs or the black market.","The shift from flowers to extracts such as Sativex or Epidiolex is often clinically unsuitable for patients with acute breakthrough pain because extracts have a delayed onset of action. Dr Greif described this as a social disparity, saying patients who depend on rapid-acting flower inhalation are pushed into the out-of-pocket market, and those unable to afford private flower prescriptions face a stark dilemma between home cultivation exceeding the legal 50g threshold or turning back to the illicit market.","The new BStabG regulations require a mandatory six-month trial with authorised finished pharmaceuticals before GKV reimbursement can be granted for specials, granting Exilby an immediate regulatory fast-track. However, Dr Greif said this creates a severe mismatch with established medical guidelines and remains highly disputed, with the BvCW working on a request for clarification to the Federal Ministry of Health regarding potential off-label prescribing during the trial period.","Exilby, also known as VER-01, contains over 100 compounds, compared to the single or dual compound CBD\u002FTHC combinations of other approved cannabis medicines. In clinical trials it was found to alleviate pain more effectively than opioids and improve sleep. Business of Cannabis has approached Vertanical for comment and is yet to receive a response.","2026-08-27T20:02:03.632Z","Vertanical's Exilby oral extract debuts weeks after dried cannabis flowers lost national health reimbursement, giving the new pharmaceutical a regulatory edge but raising patient access concerns.",{"brands":230,"products":234,"markets":235,"organizations":236},[231,232,233],"Exilby","Sativex","Epidiolex",[231,232,233],[178],[237,238,173],"Branchenverband Cannabiswirtschaft (BvCW)","Federal Ministry of Health","Germany's New Cannabis Medicine Exilby Launches Amid Reimbursement Shake-Up","Exilby oral extract packaging for chronic lower back pain in Germany",[242,246,249,252,255],{"claim":243,"sourceUrl":244,"_id":245},"Vertanical's Exilby oral extract for chronic lower back pain is set to debut in Germany within weeks, making it the first new European cannabis-based pharmaceutical in over five years.","https:\u002F\u002Fbusinessofcannabis.com\u002Fis-it-an-open-goal-for-germanys-new-cannabis-medicine\u002F","6a9097bbe81f0249cd72d374",{"claim":247,"sourceUrl":244,"_id":248},"Dried cannabis flowers were removed from Germany's national health reimbursement programme under BStabG regulations on 30 July 2026.","6a9097bbe81f0249cd72d375",{"claim":250,"sourceUrl":244,"_id":251},"The BStabG regulations require a mandatory six-month trial with authorised finished pharmaceuticals before GKV reimbursement can be granted for specials.","6a9097bbe81f0249cd72d376",{"claim":253,"sourceUrl":244,"_id":254},"An estimated 800,000 patients secure medical cannabis in Germany, with about 250,000 obtaining GKV reimbursement and roughly 65,000 of those previously on cannabis flowers.","6a9097bbe81f0249cd72d377",{"claim":256,"sourceUrl":244,"_id":257},"Exilby (VER-01) contains over 100 compounds and in clinical trials was found to alleviate pain more effectively than opioids and improve sleep.","6a9097bbe81f0249cd72d378",{"title":259,"description":260},"Germany's Exilby Launch Amid Cannabis Reimbursement Shift","Vertanical's Exilby oral extract debuts in Germany weeks after dried cannabis flowers lost national health reimbursement, raising patient access concerns.",[262],{"name":186,"url":244,"trustTier":39,"_id":263},"6a9097bbe81f0249cd72d373","German company Vertanical is set to launch Exilby, the first new European cannabis-based pharmaceutical in over five years, for chronic lower back pain. The launch follows the removal of dried cannabis flowers from Germany's national health reimbursement programme under BStabG regulations, creating a regulatory advantage for finished pharmaceuticals like Exilby. Industry representatives warn the shift may increase costs and push patients toward the black market.","2026-08-28T05:26:14.616Z",{"_id":267,"slug":268,"articleType":269,"body":270,"createdAt":278,"dek":279,"entities":280,"headline":295,"imageAlt":296,"imageUrl":24,"keyFacts":297,"language":33,"publishedAt":72,"seo":314,"sources":317,"summary":320,"updatedAt":321},"6a9097d8aeddfad21a39f9d3","aurora-cannabis-buys-uk-pharmacy-and-import-licence-for-2-1m-124d24b8","m_and_a",[271,272,273,274,275,276,277],"Aurora Cannabis has completed dual acquisitions in the UK worth £2.1m, taking direct ownership of a licensed importer and wholesaler alongside a licensed pharmacy for the first time in what it calls 'a very important growth market'. On August 19, 2026, the Canadian LP acquired 100% of the shares in Birmingham-based Internod Pharma and HAP Pharma in an all-cash deal.","Andreas Dotterweich, Aurora's Senior Vice President, said the acquisition was designed to shorten the distance between the company and the UK's patient population. 'It is being a lot closer to the patient,' he said. 'At the end of the day, it's patient demand, and you want to have a direct route to the patient, and the direct route to market… it gives us also control and ownership of the key import, distribution, and pharmacy capabilities.'","Internod Pharma holds UK Wholesale Dealer's Authorisation 58825, granted by the MHRA on August 14, 2024, covering the import, holding and supply of prescription-only medicines, including narcotic and psychotropic products, from an operating site in Oldbury. That licence is the key asset behind the acquisition, giving Aurora the right to import and distribute medical cannabis product into the UK without routing them through a third-party wholesaler.","HAP Pharma is described as 'a licensed pharmacy', but has filed dormant company accounts since incorporation in April 2020, suggesting no significant trading activity. Internod Pharma's latest accounts show £30,872 in equipment at cost by March 2026, trade creditors, and a small debtor book, though its turnover has never been made public.","The acquisition follows a period of rapid growth in Aurora's European business. Europe accounted for 47.5% of Aurora's net revenue in the quarter ended June 30, 2026, up from 33.7% a year earlier, while Canada's share fell from 49.9% to 35.9% over the same period. Germany drove the shift, with Aurora's international medical cannabis revenue rising 17% to CA$43.3m.","CEO Miguel Martin said the transaction marked the latest evolution of Aurora's long-term strategy, moving away from Canadian adult-use markets towards medical cannabis markets flourishing across Europe. 'We believe that this transaction will allow us to fully leverage our operational, commercial and regulatory expertise to expand our market share, while also supporting a consistent and reliable supply of high-quality medical cannabis products to UK patients,' Martin explained.","Asked whether the deal would translate into lower prices for patients, Dotterweich said it was 'a bit early to give a concrete answer to that', but that it meant 'better access for the patients, definitely, also especially with the pharmacy'. He emphasised that the UK is 'a very important growth market for Aurora' and that the acquisition strengthens Aurora's platform to navigate regulatory shifts.","2026-08-27T20:02:32.313Z","The Canadian producer acquires Internod Pharma and HAP Pharma to secure direct import, distribution, and pharmacy capabilities in the UK medical cannabis market.",{"brands":281,"products":285,"markets":286,"organizations":289},[282,283,284],"Aurora Cannabis","Curaleaf Holdings","Safari Flower Company",[],[287,178,179,288],"UK","Poland",[290,291,292,186,293,294],"Internod Pharma","HAP Pharma","MHRA","Zuanic & Associates","Veterans Affairs Canada","Aurora Cannabis Buys UK Pharmacy and Import Licence for £2.1m","Aurora Cannabis signage outside a UK pharmacy, representing the company's £2.1m acquisition of Internod Pharma and HAP Pharma to secure direct patient access.",[298,302,305,308,311],{"claim":299,"sourceUrl":300,"_id":301},"Aurora Cannabis acquired 100% of Internod Pharma and HAP Pharma in an all-cash deal worth £2.1m on August 19, 2026.","https:\u002F\u002Fbusinessofcannabis.com\u002Faurora-buys-uk-pharmacy-and-import-licence-for-2-1m-securing-direct-route-to-patients\u002F","6a9097d8e81f0249cd72d3cc",{"claim":303,"sourceUrl":300,"_id":304},"Internod Pharma holds UK Wholesale Dealer's Authorisation 58825, granted by the MHRA on August 14, 2024, covering the import, holding and supply of prescription-only medicines including narcotic and psychotropic products.","6a9097d8e81f0249cd72d3cd",{"claim":306,"sourceUrl":300,"_id":307},"Europe accounted for 47.5% of Aurora's net revenue in the quarter ended June 30, 2026, up from 33.7% a year earlier.","6a9097d8e81f0249cd72d3ce",{"claim":309,"sourceUrl":300,"_id":310},"Aurora's international medical cannabis revenue rose 17% to CA$43.3m, with growth concentrated in Germany.","6a9097d8e81f0249cd72d3cf",{"claim":312,"sourceUrl":300,"_id":313},"HAP Pharma has filed dormant company accounts since incorporation in April 2020, suggesting no significant trading activity.","6a9097d8e81f0249cd72d3d0",{"title":315,"description":316},"Aurora Buys UK Pharmacy and Import Licence for £2.1m","Aurora Cannabis acquires Internod Pharma and HAP Pharma for £2.1m, securing direct import, distribution, and pharmacy capabilities in the UK medical cannabis market.",[318],{"name":186,"url":300,"trustTier":39,"_id":319},"6a9097d8e81f0249cd72d3cb","Aurora Cannabis has acquired 100% of Birmingham-based Internod Pharma and HAP Pharma in an all-cash deal worth £2.1m, giving it direct ownership of a licensed importer, wholesaler, and pharmacy in the UK for the first time. The deal, announced on August 19, 2026, is designed to shorten the distance between Aurora and UK patients as the company shifts focus from Canadian adult-use to European medical cannabis markets.","2026-08-28T05:26:14.622Z",{"_id":323,"slug":324,"articleType":269,"body":325,"createdAt":334,"dek":335,"entities":336,"headline":349,"imageAlt":350,"imageUrl":24,"keyFacts":351,"language":33,"publishedAt":72,"seo":371,"sources":374,"summary":377,"updatedAt":378},"6a9097fcaeddfad21a39f9d4","aurora-accuses-curaleaf-of-pressuring-shareholders-as-official-takeover-bid-launches-6d25d076",[326,327,328,329,330,331,332,333],"Curaleaf Holdings formally launched its unsolicited takeover bid for Aurora Cannabis on August 18, 2026, giving Aurora shareholders until December 1, 2026 to decide whether to tender their shares.","The offer combines 0.3463 of a Curaleaf share and US$0.75 in cash for each Aurora share, together worth US$4.00, representing a 45% premium to Aurora's unaffected 30-day volume-weighted price of US$2.75, or 110% once Aurora's cash pile is stripped out.","Aurora's board has formed a special committee of independent directors and urged shareholders to take no action before it makes a formal recommendation, expected within 15 days of the bid's launch, around September 2.","Aurora CEO Miguel Martin accused Curaleaf of making its offer public to pressure shareholders into a short-term decision for the benefit of Curaleaf shareholders, stating that Curaleaf's objective is to acquire Aurora's EU-GMP facilities and medical cannabis platforms at the lowest price possible.","Curaleaf's Boris Jordan defended the bid price by citing significant headwinds for Aurora in Canada and Germany, including the cancellation of German medical cannabis reimbursement and reduced Canadian medical cannabis reimbursement rates.","For the deal to close, more than half of Aurora's shareholders need to agree to sell, not counting Curaleaf's own stake, and at least two-thirds of Aurora's shares overall, including potential share conversions, must be tendered under Canadian rules.","Curaleaf says there is no financing or due-diligence condition attached to the offer, only regulatory approvals and standard closing terms, including that Aurora's shareholder rights plan, if adopted, must not interfere.","On the same day as the bid launch, Aurora announced a £2.1 million acquisition of Internode Pharma and HAP Pharma, a licensed importer and pharmacy in Birmingham, giving it direct ownership of the UK supply chain from import through to patient dispensing.","2026-08-27T20:03:08.543Z","Curaleaf has formally launched its unsolicited bid for Aurora Cannabis, setting a December 1 deadline while Aurora urges shareholders to take no action.",{"brands":337,"products":339,"markets":340,"organizations":341},[338,282],"Curaleaf",[],[179,178,287],[283,282,342,293,343,344,345,346,347,348,291],"Prohibition Partners","Torys LLP","Stikeman Elliott","Paul, Weiss","Fort Capital Partners","Kingsdale Advisors","Internode Pharma","Aurora Accuses Curaleaf of Pressuring Shareholders as Official Takeover Bid Launches","Curaleaf and Aurora Cannabis corporate logos side by side, representing the unsolicited takeover bid.",[352,356,359,362,365,368],{"claim":353,"sourceUrl":354,"_id":355},"Curaleaf formally launched its takeover bid for Aurora Cannabis on August 18, 2026, with the offer open until December 1, 2026.","https:\u002F\u002Fbusinessofcannabis.com\u002Faurora-accuses-curaleaf-of-pressuring-shareholders-as-it-launches-official-takeover-bid\u002F","6a9097fce81f0249cd72d42b",{"claim":357,"sourceUrl":354,"_id":358},"Curaleaf's offer combines 0.3463 of a Curaleaf share and US$0.75 in cash for each Aurora share, together worth US$4.00, a 45% premium to Aurora's unaffected 30-day volume-weighted price.","6a9097fce81f0249cd72d42c",{"claim":360,"sourceUrl":354,"_id":361},"Aurora's board has urged shareholders to take no action before it makes a formal recommendation, expected within 15 days of the bid's launch.","6a9097fce81f0249cd72d42d",{"claim":363,"sourceUrl":354,"_id":364},"Aurora CEO Miguel Martin accused Curaleaf of making its offer public to pressure shareholders into making a short-term decision for the benefit of Curaleaf shareholders.","6a9097fce81f0249cd72d42e",{"claim":366,"sourceUrl":354,"_id":367},"The bid values Aurora at roughly US$236 million on a basic-share basis, though that could change once outstanding options and warrants are counted.","6a9097fce81f0249cd72d42f",{"claim":369,"sourceUrl":354,"_id":370},"Aurora announced a £2.1 million acquisition of Internode Pharma and HAP Pharma, giving it direct ownership of the UK supply chain from import through to patient dispensing.","6a9097fce81f0249cd72d430",{"title":372,"description":373},"Aurora Accuses Curaleaf of Pressuring Shareholders","Curaleaf launches official takeover bid for Aurora Cannabis, offering US$4.00 per share. Aurora urges shareholders to take no action pending review.",[375],{"name":186,"url":354,"trustTier":39,"_id":376},"6a9097fce81f0249cd72d42a","Curaleaf Holdings has submitted an official takeover bid for Aurora Cannabis, offering 0.3463 Curaleaf shares plus US$0.75 cash per Aurora share, valued at roughly US$236 million. Aurora's board has told shareholders to take no action pending a formal recommendation expected around September 2, while CEO Miguel Martin accused Curaleaf of pressuring shareholders into a short-term decision.","2026-08-28T05:26:14.629Z",{"_id":380,"slug":381,"articleType":382,"body":383,"createdAt":391,"dek":392,"entities":393,"headline":410,"imageAlt":411,"imageUrl":24,"keyFacts":412,"language":33,"publishedAt":72,"seo":429,"sources":432,"summary":436,"updatedAt":437},"6a909847aeddfad21a39f9d6","ireland-s-dunbar-pharma-launches-first-plant-derived-dronabinol-in-uk-through-ips-pharma-a3c1a445","product_launch",[384,385,386,387,388,389,390],"Dunbar Pharmaceuticals, an Irish pharmaceutical cannabis manufacturer, has launched the first plant-derived dronabinol active ingredient into the UK market through a partnership with Specials manufacturer IPS Pharma. The WaterClear THC products are now available to clinicians across the UK for the first time.","Dronabinol, the international non-proprietary name for delta-9-THC in purified pharmaceutical form, has been approved in the US for chemotherapy-induced nausea since 1985. Until now, commercial-scale supply of the drug has been almost entirely synthetic.","Dunbar's WaterClear range is manufactured under Health Products Regulatory Authority oversight at its EU-GMP facility in Athlone, Ireland. The product is a chemically defined, pharmacopoeia-grade active ingredient produced from plant starting material rather than through chemical synthesis, offering predictable milligram dosing and minimal compositional variability.","Leah Fletcher, Founder and Chief Executive Officer of Dunbar Pharma, said many patients cannot or do not wish to inhale cannabinoid medicines and should have access to suitable alternatives. She noted that manufacturing at commercial scale in Ireland to EU GMP standards provides partners such as IPS Pharma with a consistent, reliable supply of dronabinol for oral formulations.","The launch comes amid a visible shift toward pharma-grade cannabinoid formulations across European markets. In Germany, where Dunbar entered earlier in 2026, the category that includes dronabinol recorded more statutory health insurance prescriptions than cannabis flower over the course of 2025.","Fletcher argued that the UK's regulatory route is still lagging behind more flexible markets like Germany. UK Specials manufacturers must allocate 90 days to a patient-specific prescription and cannot compound in anticipation of demand, whereas German pharmacies operating under the magisterial preparation route can manufacture ahead of time based on previous prescription volumes.","The UK launch lands ahead of the Advisory Council on the Misuse of Drugs' expected review of medical cannabis, which Fletcher said she hopes will produce more structure, rigour, and clear guidelines for people supplying to the market.","2026-08-27T20:04:23.695Z","Dunbar Pharmaceuticals' WaterClear THC range brings plant-derived dronabinol capsules, oral spray, and dropper solution to UK clinicians via IPS Pharma.",{"brands":394,"products":398,"markets":403,"organizations":405},[395,396,397],"Dunbar Pharma","IPS Pharma","WaterClear THC",[399,400,401,402],"WaterClear THC 5 mg oral capsules","WaterClear THC 10 mg oral capsules","WaterClear THC 25 mg\u002FmL oral spray","WaterClear THC 25 mg\u002FmL oily dropper solution",[287,404,178],"Ireland",[406,396,407,408,409],"Dunbar Pharmaceuticals","Health Products Regulatory Authority","Advisory Council on the Misuse of Drugs","Enterprise Ireland","Ireland's Dunbar Pharma Launches First Plant-Derived Dronabinol in UK Through IPS Pharma","WaterClear THC plant-derived dronabinol products from Dunbar Pharma, including oral capsules, oral spray, and dropper solution, launched in the UK through IPS Pharma.",[413,417,420,423,426],{"claim":414,"sourceUrl":415,"_id":416},"Dunbar Pharmaceuticals has launched the first plant-derived dronabinol active ingredient into the UK market in partnership with IPS Pharma.","https:\u002F\u002Fbusinessofcannabis.com\u002Firelands-dunbar-pharma-launches-first-plant-derived-dronabinol-in-uk-through-ips-pharma\u002F","6a909847e81f0249cd72d58c",{"claim":418,"sourceUrl":415,"_id":419},"The WaterClear THC range includes 5 mg and 10 mg oral capsules, a 25 mg\u002FmL oral spray, and a 25 mg\u002FmL oily dropper solution.","6a909847e81f0249cd72d58d",{"claim":421,"sourceUrl":415,"_id":422},"Dunbar's product is manufactured under Health Products Regulatory Authority oversight at its EU-GMP facility in Athlone, Ireland.","6a909847e81f0249cd72d58e",{"claim":424,"sourceUrl":415,"_id":425},"Dronabinol has been approved in the US for chemotherapy-induced nausea since 1985.","6a909847e81f0249cd72d58f",{"claim":427,"sourceUrl":415,"_id":428},"In Germany, the category that includes dronabinol recorded more statutory health insurance prescriptions than cannabis flower over the course of 2025.","6a909847e81f0249cd72d590",{"title":430,"description":431},"Dunbar Pharma Launches Plant-Derived Dronabinol in UK","Irish manufacturer Dunbar Pharmaceuticals launches first plant-derived dronabinol in the UK through IPS Pharma, offering WaterClear THC capsules, spray, and dropper.",[433],{"name":186,"url":434,"trustTier":39,"_id":435},"https:\u002F\u002Fbusinessofcannabis.com\u002Firelands-dunbar-pharma-launches-plant-derived-dronabinol-in-uk-through-ips-pharma\u002F","6a909847e81f0249cd72d58b","Irish pharmaceutical cannabis manufacturer Dunbar Pharmaceuticals has launched the first plant-derived dronabinol active ingredient into the UK market in partnership with IPS Pharma. The WaterClear THC range includes 5 mg and 10 mg oral capsules, a 25 mg\u002FmL oral spray, and a 25 mg\u002FmL oily dropper solution, manufactured at Dunbar's EU-GMP facility in Athlone, Ireland.","2026-08-28T05:26:14.637Z",{"_id":439,"slug":440,"articleType":46,"body":441,"createdAt":450,"dek":451,"entities":452,"headline":467,"imageAlt":468,"imageUrl":24,"keyFacts":469,"language":33,"publishedAt":72,"seo":486,"sources":489,"summary":492,"updatedAt":493},"6a909867aeddfad21a39f9d7","uk-medical-cannabis-prescriptions-hit-1-7-million-in-2025-as-acmd-review-approaches-547cd49a",[442,443,444,445,446,447,448,449],"More than a year after the Advisory Council on the Misuse of Drugs was commissioned to review the UK medical cannabis industry, new Freedom of Information data reveals the scale of a market that has continued to expand with minimal political scrutiny. The private unlicensed specials market grew by 154% between 2024 and 2025, from 668,511 items to 1,701,064 dispensed in English community pharmacies, according to NHS Business Services Authority data secured by Prohibition Partners.","The growth curve has steepened since 2019, when just 278 items were dispensed in the first full calendar year of private unlicensed cannabis at scale. By January 2026, the most recent month of complete data, English community pharmacies dispensed 80,331 items, suggesting an annualised run rate of just under one million items. The NHSBSA cautions that figures may be revised upward as prescriptions are submitted in later months.","Supply-side data from the Home Office tracks the same trajectory. UK imports of unlicensed cannabis flower reached 30,120 kg in 2025, up from 15,025 kg in 2024. Canada is now the source of 57% of that volume, shipping 17,067 kg directly to the UK, up from 2,579 kg the year before. Portugal grew its shipments ten-fold since 2023 to 3,971 kg, while Spain, once the dominant European processing hub, saw quarterly volumes fall from 1,570 kg in Q1 2025 to 252 kg in Q4.","For the first time, Home Office data also captures Δ9-tetrahydrocannabinol extracts, tracked separately only since 2024 following changes to INCB international reporting standards. Extract imports rose from 114.3 kg in 2024 to 395.5 kg in 2025, a 246% year-on-year increase. Spain led on volume with 156.1 kg, but Canadian extract shipments rose 32-fold from 4.8 kg to 152.3 kg in a single year.","Comparing the two datasets, community pharmacies dispensed approximately 19.4 tonnes of flower to patients across 1.4 million flower items in 2025, an average of 13.7 grams per item. Against 30.1 tonnes imported, the roughly 10.8-tonne gap maps closely to Q4 2025's import volume of 11,898 kg, pointing to wholesale-scale year-end build-up in the supply chain ahead of Q1 2026 dispensing.","The raw NHSBSA dataset contained more than 375,000 line items across seven years and captured 10,190 distinct product name entries in 2025 alone. Most are duplicates of the same underlying products entered under slight variations in spelling, potency notation and volume, because unlicensed prescriptions are captured as free-text on the NHS system and only identified as cannabis through subsequent manual review.","The ACMD's November 2020 review recommended a CBPM patient registry as crucial for future assessments, but when the registry launched in mid-2025 it captured around 1,000 NHS patients on Sativex, Epidyolex and Nabilone and explicitly excluded the estimated 60,000-plus private patients through which the market has actually grown. For an estimated 100,000 UK patients receiving treatment in 2025, the 10,190 distinct product-name variants describe a therapeutic landscape without cross-clinic pharmacopoeia or generic equivalence.","If the ACMD review is published on schedule at the end of summer 2026, it will coincide with the two most consequential years for the UK medical cannabis industry since 2018. The ecosystem has evolved around guidelines that were never intended to regulate a market of this scale.","2026-08-27T20:04:55.923Z","Private unlicensed cannabis dispensing in England grew 154% year-on-year, while imports of flower and THC extracts surged ahead of a landmark regulatory review.",{"brands":453,"products":454,"markets":460,"organizations":463},[],[455,456,457,458,459],"cannabis flower","THC extracts","oils","tinctures","cartridge preparations",[287,179,180,183,181,461,462],"North Macedonia","Australia",[464,292,465,466,342,186],"ACMD","NHSBSA","Home Office","UK Medical Cannabis Prescriptions Hit 1.7 Million in 2025 as ACMD Review Approaches","Chart showing growth in UK private unlicensed cannabis prescriptions from 278 items in 2019 to 1.7 million in 2025, alongside rising import volumes.",[470,474,477,480,483],{"claim":471,"sourceUrl":472,"_id":473},"Private unlicensed cannabis items dispensed in English community pharmacies grew 154% between 2024 and 2025, from 668,511 to 1,701,064 items.","https:\u002F\u002Fbusinessofcannabis.com\u002Fuk-medical-cannabis-prescriptions-hit-1-7-million-in-2025-as-acmd-review-approaches\u002F","6a909867e81f0249cd72d604",{"claim":475,"sourceUrl":472,"_id":476},"UK imports of unlicensed cannabis flower reached 30,120 kg in 2025, up from 15,025 kg in 2024, with Canada supplying 57% of the 2025 total.","6a909867e81f0249cd72d605",{"claim":478,"sourceUrl":472,"_id":479},"UK Δ9-THC extract imports rose 246% year-on-year, from 114.3 kg in 2024 to 395.5 kg in 2025.","6a909867e81f0249cd72d606",{"claim":481,"sourceUrl":472,"_id":482},"The NHSBSA dataset captured 10,190 distinct product name entries in 2025 alone, most of which are duplicates of the same underlying products entered under slight variations.","6a909867e81f0249cd72d607",{"claim":484,"sourceUrl":472,"_id":485},"The CBPM patient registry launched in mid-2025 captured around 1,000 NHS patients and explicitly excluded the estimated 60,000-plus private patients.","6a909867e81f0249cd72d608",{"title":487,"description":488},"UK Cannabis Prescriptions Hit 1.7M in 2025","English pharmacies dispensed 1.7M private cannabis items in 2025, up 154%, as flower imports hit 30 tonnes and the ACMD review nears.",[490],{"name":186,"url":472,"trustTier":39,"_id":491},"6a909867e81f0249cd72d603","New Freedom of Information data shows English community pharmacies dispensed 1,701,064 private unlicensed cannabis items in 2025, up 154% from 2024. UK imports of unlicensed cannabis flower reached 30,120 kg, with Canada supplying 57%, and THC extract imports rose 246% to 395.5 kg. The figures land as the Advisory Council on the Misuse of Drugs nears its scheduled summer 2026 review of the UK medical cannabis framework.","2026-08-28T05:26:14.643Z",{"_id":495,"slug":496,"articleType":269,"body":497,"createdAt":504,"dek":505,"entities":506,"headline":515,"imageAlt":516,"imageUrl":24,"keyFacts":517,"language":33,"publishedAt":72,"seo":537,"sources":540,"summary":543,"updatedAt":544},"6a909898aeddfad21a39f9d8","curaleaf-s-unsolicited-aurora-bid-targets-europe-s-medical-cannabis-leadership-5b5f7183",[498,499,500,501,502,503],"Curaleaf Holdings has launched an unsolicited takeover bid for rival Aurora Cannabis, a move that would reshape the European medical cannabis landscape. On August 11, Curaleaf informed investors of its intention to offer US$4.00 per share for all issued and outstanding Aurora shares, a proposal Chairman and CEO Boris Jordan called a 'win-win' for both sets of shareholders.","Aurora responded within hours, disputing Curaleaf's account of their private discussions and confirming that its board would form a special committee of independent directors to evaluate the proposal. The offer combines 0.3463 of a Curaleaf share and US$0.75 in cash for each Aurora share, representing a 45% premium to Aurora's 30-day volume-weighted average price of US$2.75. Excluding cash on Aurora's balance sheet, Curaleaf calculates the premium at 110%.","Based on 58.9 million Aurora shares outstanding as of March 31, 2026, the bid values Aurora at approximately US$236 million on a basic-share basis. That figure is modest compared with earlier industry deals: Aphria's 2020 merger with Tilray was worth roughly US$3.9 billion, and Aurora's own 2018 purchase of MedReleaf was reported at between US$2.5 billion and US$3.2 billion. It is also the first hostile approach by a leading cannabis company since Green Growth Brands' failed 2019 bid for Aphria.","The strategic logic centres on Europe, where medical cannabis sales are forecast by Prohibition Partners to more than double by 2028. Aurora has pivoted almost entirely to international medical cannabis, with medical operations accounting for 90% of full-year revenue. The company holds the number one market share position in Poland, operates EU-GMP certified manufacturing through its Pedanios unit in Germany, and has secured EU Community Plant Variety Rights for two proprietary strains.","Curaleaf's international arm posted US$172.5 million in revenue for 2025, up 63% year-on-year, driven by its position as Germany's largest single flower supplier and its UK clinic network. Jordan said the combination would unlock at least US$40 million in annual cost and revenue synergies, creating a pro forma company with trailing 12-month revenue of US$1.5 billion and adjusted EBITDA of US$350 million across 17 countries.","Aurora's shares rose 22% to US$3.48 on the day of the announcement and added a further 9.61% the following session to US$3.82, still below the US$4.00 offer price. Analysts at TD Cowen wrote that the offer 'does not fully capture Aurora's long-term intrinsic value,' citing its medical cannabis leadership and genetics portfolio. Aurora's special committee review is the next milestone to watch.","2026-08-27T20:05:44.096Z","A US$236 million hostile offer would combine two of the continent's largest medical cannabis operators, but Aurora's board is not yet convinced.",{"brands":507,"products":509,"markets":511,"organizations":513},[338,282,508,284],"Pedanios",[510],"QMID inhalation device",[178,288,287,182,183,512,179,180],"Turkey",[514,342],"TD Cowen","Curaleaf's Unsolicited Aurora Bid Targets Europe's Medical Cannabis Leadership","Curaleaf and Aurora Cannabis logos side by side, representing a potential merger in the European medical cannabis market.",[518,522,525,528,531,534],{"claim":519,"sourceUrl":520,"_id":521},"Curaleaf announced an unsolicited takeover bid for Aurora Cannabis at US$4.00 per share on August 11.","https:\u002F\u002Fbusinessofcannabis.com\u002Fcuraleafs-aurora-bid-is-a-fight-for-europes-cannabis-crown\u002F","6a909898e81f0249cd72d66a",{"claim":523,"sourceUrl":520,"_id":524},"The offer values Aurora at roughly US$236 million based on 58.9 million shares outstanding.","6a909898e81f0249cd72d66b",{"claim":526,"sourceUrl":520,"_id":527},"Aurora's board formed a special committee of independent directors to review the proposal.","6a909898e81f0249cd72d66c",{"claim":529,"sourceUrl":520,"_id":530},"Aurora's medical operations accounted for 90% of full-year revenue, with the number one market share position in Poland.","6a909898e81f0249cd72d66d",{"claim":532,"sourceUrl":520,"_id":533},"Curaleaf International posted US$172.5 million in 2025 revenue, up 63% year-on-year, driven by Germany and the UK.","6a909898e81f0249cd72d66e",{"claim":535,"sourceUrl":520,"_id":536},"TD Cowen analysts said the offer does not fully capture Aurora's long-term intrinsic value.","6a909898e81f0249cd72d66f",{"title":538,"description":539},"Curaleaf's Aurora Bid Targets Europe's Cannabis Crown","Curaleaf's US$236M unsolicited bid for Aurora Cannabis aims to consolidate European medical cannabis leadership, but Aurora's board is reviewing the offer.",[541],{"name":186,"url":520,"trustTier":39,"_id":542},"6a909898e81f0249cd72d669","Curaleaf Holdings announced an unsolicited takeover bid for Aurora Cannabis at US$4.00 per share, valuing the deal at roughly US$236 million. The move aims to consolidate leading positions in Germany, Poland, and the UK, but Aurora has formed a special committee to review the offer, and analysts say the price may undervalue Aurora's medical cannabis franchise.","2026-08-28T05:26:14.648Z",{"_id":546,"slug":547,"articleType":548,"body":549,"createdAt":555,"dek":556,"entities":557,"headline":564,"imageAlt":565,"imageUrl":24,"keyFacts":566,"language":33,"publishedAt":72,"seo":580,"sources":583,"summary":587,"updatedAt":588},"6a9098b7aeddfad21a39f9d9","gallup-17-of-americans-smoke-cannabis-15-consume-edibles-8ba8291a","research",[550,551,552,553,554],"Seventeen percent of Americans said they smoke cannabis, according to a Gallup poll released Monday, tying the previous record high found by the pollster in 2023. The smoking rate had dipped to 13% in 2024 before rising to 14% in 2025.","Another 15% of those polled indicated they consume cannabis edibles. The edible figure includes 17% of women and 12% of men, while 15% of women and 18% of men said they smoked cannabis.","The majority of respondents who either smoked or consumed edibles were 30 to 49 years old, at 25% and 20% respectively. Among 18- to 29-year-olds, 23% said they smoked cannabis and 19% said they ate edibles. For adults 50 to 64, 10% reported smoking and 12% reported edible consumption, while the lowest rates were among those 65 and older at 5% and 7%.","Cannabis consumption was more popular among non-college graduates than college graduates. Twenty percent of the non-college graduate cohort said they smoke cannabis and 17% consume edibles, compared to 11% and 12% respectively among college graduates.","The poll found Americans about evenly split on the effect of cannabis on most consumers, with 47% saying it has a very or somewhat positive effect and 46% saying it has a very or somewhat negative effect. U.S. adults were also split in the two previous polls, with a slight positive lean of 53% in 2022 and a slight negative lean of 51% in 2024.","2026-08-27T20:06:15.180Z","Smoking ties the pollster's record high while edibles show a gender gap, with women outpacing men.",{"brands":558,"products":559,"markets":560,"organizations":562},[],[],[561],"United States",[563],"Gallup","Gallup: 17% of Americans Smoke Cannabis, 15% Consume Edibles","Bar chart showing Gallup poll results: 17% of Americans smoke cannabis and 15% consume edibles, with age and gender breakdowns.",[567,571,574,577],{"claim":568,"sourceUrl":569,"_id":570},"17% of Americans said they smoke cannabis, tying the previous record high found by Gallup in 2023.","https:\u002F\u002Fganjapreneur.com\u002Fgallup-17-of-americans-smoke-cannabis-15-consume-edibles\u002F","6a9098b7e81f0249cd72d6a3",{"claim":572,"sourceUrl":569,"_id":573},"15% of Americans indicated they consume cannabis edibles, including 17% of women and 12% of men.","6a9098b7e81f0249cd72d6a4",{"claim":575,"sourceUrl":569,"_id":576},"The majority of respondents who smoked or consumed edibles were 30 to 49 years old, at 25% and 20% respectively.","6a9098b7e81f0249cd72d6a5",{"claim":578,"sourceUrl":569,"_id":579},"47% of Americans say cannabis has a very or somewhat positive effect on most consumers, while 46% say it has a very or somewhat negative effect.","6a9098b7e81f0249cd72d6a6",{"title":581,"description":582},"Gallup: 17% of Americans Smoke Cannabis","A new Gallup poll finds 17% of U.S. adults smoke cannabis and 15% consume edibles, with consumption highest among adults aged 30–49.",[584],{"name":585,"url":569,"trustTier":39,"_id":586},"Ganjapreneur","6a9098b7e81f0249cd72d6a2","A new Gallup poll finds 17% of U.S. adults say they smoke cannabis, tying the record high from 2023, while 15% report consuming cannabis edibles. Consumption is highest among adults aged 30–49, and Americans remain closely divided on whether cannabis has a positive or negative effect on most users.","2026-08-28T05:26:14.654Z",{"_id":590,"slug":591,"articleType":548,"body":592,"createdAt":597,"dek":598,"entities":599,"headline":608,"imageAlt":609,"imageUrl":24,"keyFacts":610,"language":33,"publishedAt":72,"seo":624,"sources":627,"summary":630,"updatedAt":631},"6a9098ddaeddfad21a39f9da","medical-cannabis-access-linked-to-7-drop-in-health-related-work-absences-study-finds-f991f0e3",[593,594,595,596],"Health-related work absences dropped by roughly 7% in states with medical cannabis access, according to a University of Georgia study published in the Journal of Workplace and Behavioral Health. The research drew on responses from more than 20 million people in a U.S. Census Bureau and U.S. Bureau of Labor Statistics dataset spanning 1990 to 2025.","The effect was strongest in physically demanding occupations, including manual labor and machinery operation, and in industries such as construction and agriculture. Health service workers also showed significant declines in health-related absences.","Patryk Babiarz, the study's corresponding author and an associate professor in the UGA College of Family and Consumer Sciences, said work absenteeism costs employers heavily, with one estimate placing the total at $225 billion annually in lost productivity alone. He added that medical marijuana could save hundreds of millions of dollars in economic cost simply because people are not missing work.","Researchers suggested that access to medical cannabis could be reducing symptoms associated with chronic pain, alleviating the need to take sick leave, though the data could not directly confirm cannabis use for pain management. Adult-use cannabis laws did not influence health-related absenteeism, regardless of whether cannabis was legal for retail sale or simply decriminalized. The study did not examine potential adverse effects of cannabis use, such as negative health and behavioral outcomes.","2026-08-27T20:06:53.207Z","A University of Georgia analysis of more than 20 million survey responses finds fewer sick days in states with medical cannabis laws, with the strongest effect in physically demanding jobs.",{"brands":600,"products":601,"markets":602,"organizations":604},[],[],[603],"medical cannabis",[605,606,607],"University of Georgia","U.S. Census Bureau","U.S. Bureau of Labor Statistics","Medical Cannabis Access Linked to 7% Drop in Health-Related Work Absences, Study Finds","A worker in a physically demanding job, such as construction or agriculture, representing reduced health-related work absences in states with medical cannabis access.",[611,615,618,621],{"claim":612,"sourceUrl":613,"_id":614},"Health-related work absences dropped by about 7% in states with medical cannabis access.","https:\u002F\u002Fganjapreneur.com\u002Fstudy-health-related-work-absences-drop-7-in-states-with-medical-cannabis-access\u002F","6a9098dde81f0249cd72d6e5",{"claim":616,"sourceUrl":613,"_id":617},"The study analyzed responses from more than 20 million people in a U.S. Census Bureau and U.S. Bureau of Labor Statistics dataset between 1990 and 2025.","6a9098dde81f0249cd72d6e6",{"claim":619,"sourceUrl":613,"_id":620},"The effect was strongest in physically demanding occupations, such as manual labor and machinery operation, and in industries like construction and agriculture.","6a9098dde81f0249cd72d6e7",{"claim":622,"sourceUrl":613,"_id":623},"Adult-use cannabis laws did not influence health-related absenteeism, regardless of whether cannabis was legal for retail sale or simply decriminalized.","6a9098dde81f0249cd72d6e8",{"title":625,"description":626},"Medical Cannabis Access Tied to 7% Drop in Work Absences","A University of Georgia study finds health-related work absences fell about 7% in states with medical cannabis access, with the strongest effect in physical jobs.",[628],{"name":585,"url":613,"trustTier":39,"_id":629},"6a9098dde81f0249cd72d6e4","Health-related work absences fell by about 7% in states with medical cannabis access, according to a University of Georgia study published in the Journal of Workplace and Behavioral Health. Researchers analyzed U.S. Census Bureau and Bureau of Labor Statistics data from 1990 to 2025, finding the largest reductions in manual labor, machinery operation, construction, agriculture, and health services. Adult-use laws showed no effect on absenteeism.","2026-08-28T05:26:14.658Z",{"_id":633,"slug":634,"articleType":121,"body":635,"createdAt":646,"dek":647,"entities":648,"headline":657,"imageAlt":658,"imageUrl":24,"keyFacts":659,"language":33,"publishedAt":72,"seo":676,"sources":679,"summary":682,"updatedAt":683},"6a909907aeddfad21a39f9db","university-of-maryland-sends-cease-and-desist-to-terps-usa-over-terps-trademark-and-branding-7277227f",[636,637,638,639,640,641,642,643,644,645],"The University of Maryland (UMD) sent a cease-and-desist letter in July to Terps USA, a Colorado-based cannabis terpenes brand, over the company's use of the 'TERPS' name and a red script logo the university says is 'nearly identical' to its trademark.","In the letter, UMD stated that over nearly a century the TERPS trademark has become closely associated with the university and its academic and athletic programs, and that students, faculty, staff, and alumni proudly identify as 'TERPS.'","The university said it is particularly concerned that consumers may incorrectly believe UMD has licensed, sponsored, endorsed, or is otherwise affiliated with cannabis-related products, which would materially impair the goodwill of its famous TERPS marks.","Terps USA sells liquid formulations of botanical terpenes applied as a fine mist to cannabis flower, pre-rolls, or concentrates, according to the company's attorney, Milo Schwab.","Schwab responded that the trademark registration cited by the university does not establish what UMD claims. He said the USPTO record shows the university's trademark covers only organizing and conducting college sport competitions and athletic events, and broadcast entertainment services.","Schwab also noted that UMD's registration, issued January 13, 2026, postdates Terps USA's application by more than five years and its registration by more than three. He said the university's earlier registration claiming first use in 1933 was canceled by the USPTO on March 10, 2023, for failure to file an acceptable Section 8 declaration.","From March 2023 until January 2026, the university held no federal registration for the word TERPS standing alone, Schwab said. A further Class 25 application for TERPS was filed on June 4, 2026, and remains unexamined.","Schwab added that the USPTO has repeatedly treated 'terps' as the ordinary trade designation for terpenes, placing the term on the Supplemental Register, which does not provide the same protections as the Principal Register.","He also pointed out that the color-and-style schema at issue is no longer used by Terps USA, which moved to a green-and-gold identity in July 2026 as part of a brand refresh before UMD's letter. However, the company's website still features products with the previous logo.","In an emailed statement to Ganjapreneur, Rebecca Aloisi, senior director of university communications for UMD, said the university 'won't have anything else' beyond the cease-and-desist.","2026-08-27T20:07:35.351Z","The university claims the Colorado cannabis terpenes brand's name and red-and-white script logo are 'nearly identical' to its famous TERPS marks, while the company argues the trademark covers only athletic events and was canceled for years.",{"brands":649,"products":651,"markets":652,"organizations":654},[650],"Terps USA",[],[653],"Colorado",[655,656],"University of Maryland","USPTO","University of Maryland Sends Cease-and-Desist to Terps USA Over 'TERPS' Trademark and Branding","University of Maryland cease-and-desist letter and Terps USA branding dispute over the TERPS trademark",[660,664,667,670,673],{"claim":661,"sourceUrl":662,"_id":663},"The University of Maryland sent a cease-and-desist letter to Terps USA in July over the 'TERPS' name and branding style.","https:\u002F\u002Fganjapreneur.com\u002Funiversity-of-maryland-sends-cease-and-desist-to-terpenes-brand-over-terps-and-branding-style\u002F","6a909907e81f0249cd72d77b",{"claim":665,"sourceUrl":662,"_id":666},"UMD claims Terps USA's red script logo with white and black outlines is 'very similar in appearance' to its trademarks and would confuse consumers.","6a909907e81f0249cd72d77c",{"claim":668,"sourceUrl":662,"_id":669},"Terps USA's attorney says the university's trademark registration covers only college sport competitions, athletic events, and broadcast entertainment services.","6a909907e81f0249cd72d77d",{"claim":671,"sourceUrl":662,"_id":672},"UMD's federal registration for the word TERPS was canceled by the USPTO on March 10, 2023, and the university held no federal registration for TERPS standing alone from March 2023 until January 2026.","6a909907e81f0249cd72d77e",{"claim":674,"sourceUrl":662,"_id":675},"Terps USA moved to a green-and-gold identity in July 2026 as part of a brand refresh before receiving UMD's letter.","6a909907e81f0249cd72d77f",{"title":677,"description":678},"UMD Sends Cease-and-Desist to Terps USA Over TERPS Trademark","University of Maryland demands Terps USA stop using 'TERPS' name and red script logo, claiming trademark infringement. The cannabis brand disputes the claim.",[680],{"name":585,"url":662,"trustTier":39,"_id":681},"6a909907e81f0249cd72d77a","The University of Maryland has sent a cease-and-desist letter to Terps USA, a Colorado-based cannabis terpenes brand, alleging the company's 'TERPS' name and red script logo infringe on the university's trademark. Terps USA's attorney disputes the claim, noting the university's federal registration for the word TERPS was canceled from 2023 to 2026 and covers only athletic events, not cannabis products.","2026-08-28T05:26:14.662Z",{"_id":685,"slug":686,"articleType":269,"body":687,"createdAt":693,"dek":694,"entities":695,"headline":704,"imageAlt":705,"imageUrl":24,"keyFacts":706,"language":33,"publishedAt":72,"seo":720,"sources":723,"summary":726,"updatedAt":727},"6a90991faeddfad21a39f9dc","jars-cannabis-to-acquire-sonoran-roots-creating-arizona-s-largest-dispensary-network-078d231a",[688,689,690,691,692],"JARS Cannabis has announced plans to acquire Sonoran Roots in a deal that would create the largest cannabis dispensary network in Arizona, totaling 27 locations.","As part of the acquisition, Sonoran Roots’ eight Ponderosa Dispensary locations in Chandler, Flagstaff, Glendale, Mesa, Phoenix, Queen Creek, Tempe, and Tucson will rebrand under the JARS Cannabis name.","Ronnie Kassab, CEO of JARS Cannabis, said the acquisition is “not scale for scale’s sake,” describing the combination as bringing together JARS’ retail platform with Sonoran Roots’ brand, product portfolio, and vertically integrated operation.","Michael O’Brien, currently CEO of Sonoran Roots, will become chief strategy officer of JARS. He said the companies are preserving their brands and relationships while pairing Sonoran Roots’ strengths with a retail organization that has the scale and ambition to expand further.","The transaction is expected to close by the end of the third quarter of this year and remains subject to customary closing conditions and regulatory approvals.","2026-08-27T20:07:59.887Z","The deal will rebrand eight Ponderosa Dispensary locations under JARS Cannabis and form a 27-store network across Arizona.",{"brands":696,"products":700,"markets":701,"organizations":703},[697,698,699],"JARS Cannabis","Sonoran Roots","Ponderosa Dispensary",[],[702],"Arizona",[697,698],"JARS Cannabis to Acquire Sonoran Roots, Creating Arizona’s Largest Dispensary Network","JARS Cannabis and Sonoran Roots logos alongside a map of Arizona showing the 27-dispensary network.",[707,711,714,717],{"claim":708,"sourceUrl":709,"_id":710},"JARS Cannabis is set to acquire Sonoran Roots to create a network of 27 dispensaries, the largest cannabis dispensary network in Arizona.","https:\u002F\u002Fganjapreneur.com\u002Fjars-cannabis-to-acquire-sonoran-roots-creating-arizonas-largest-dispensary-network\u002F","6a90991fe81f0249cd72d7b4",{"claim":712,"sourceUrl":709,"_id":713},"Sonoran Roots’ eight Ponderosa Dispensary locations in Chandler, Flagstaff, Glendale, Mesa, Phoenix, Queen Creek, Tempe, and Tucson will rebrand under the JARS Cannabis name.","6a90991fe81f0249cd72d7b5",{"claim":715,"sourceUrl":709,"_id":716},"Michael O’Brien, currently CEO of Sonoran Roots, will become the chief strategy officer of JARS.","6a90991fe81f0249cd72d7b6",{"claim":718,"sourceUrl":709,"_id":719},"The transaction is expected to close by the end of the third quarter of this year and is subject to customary closing conditions and regulatory approvals.","6a90991fe81f0249cd72d7b7",{"title":721,"description":722},"JARS Cannabis to Acquire Sonoran Roots in Arizona","JARS Cannabis will acquire Sonoran Roots, rebranding eight Ponderosa Dispensary locations and creating Arizona’s largest dispensary network with 27 stores.",[724],{"name":585,"url":709,"trustTier":39,"_id":725},"6a90991fe81f0249cd72d7b3","JARS Cannabis is set to acquire Sonoran Roots, combining its retail platform with Sonoran Roots’ vertically integrated operation and eight Ponderosa Dispensary locations. The transaction is expected to close by the end of the third quarter, subject to customary conditions and regulatory approvals.","2026-08-28T05:26:14.667Z",{"_id":729,"slug":730,"articleType":121,"body":731,"createdAt":736,"dek":737,"entities":738,"headline":744,"imageAlt":745,"imageUrl":24,"keyFacts":746,"language":33,"publishedAt":72,"seo":757,"sources":760,"summary":763,"updatedAt":764},"6a909933aeddfad21a39f9dd","illinois-adds-sickle-cell-disease-and-pmos-to-medical-cannabis-qualifying-conditions-5eece88d",[732,733,734,735],"The Illinois Department of Public Health (IDPH) announced Tuesday that two new conditions have been added to the state's medical cannabis qualifying conditions list: sickle cell disease and polyendocrine metabolic ovarian syndrome (PMOS) with chronic pain. The decision follows a formal petition review process that relies on expert opinion and the most up-to-date evidence to determine which debilitating conditions warrant medical cannabis access.","IDPH Director Dr. Sameer Vohra said the department reviews petitions carefully using expert opinion and current evidence to make decisions that best serve Illinois residents. He added that the agency looks forward to working with medical providers to ensure safe, appropriate access for individuals struggling with the newly approved conditions.","Sickle cell disease refers to red blood cell disorders that can lead to severe pain, fatigue, organ damage, and other complications. PMOS is a hormone health issue that can cause chronic pain. According to the department, cannabis was shown to provide relief for both conditions.","Illinois currently allows medical cannabis access for more than 50 conditions, including autism, HIV\u002FAIDS, cancer, chronic pain, Crohn's disease, endometriosis, glaucoma, lupus, migraines, multiple sclerosis, ovarian cysts, Parkinson's disease, post-traumatic stress disorder, severe fibromyalgia, and seizures characteristic of epilepsy.","2026-08-27T20:08:19.496Z","The Illinois Department of Public Health expands patient access by approving two new debilitating conditions for the state's medical cannabis program.",{"brands":739,"products":740,"markets":741,"organizations":742},[],[],[133],[743],"Illinois Department of Public Health","Illinois Adds Sickle Cell Disease and PMOS to Medical Cannabis Qualifying Conditions","Illinois Department of Public Health announces two new medical cannabis qualifying conditions: sickle cell disease and PMOS with chronic pain.",[747,751,754],{"claim":748,"sourceUrl":749,"_id":750},"The Illinois Department of Public Health added sickle cell disease and polyendocrine metabolic ovarian syndrome with chronic pain as qualifying conditions for medical cannabis.","https:\u002F\u002Fganjapreneur.com\u002Fillinois-adds-two-new-medical-cannabis-qualifying-conditions\u002F","6a909933e81f0249cd72d7d5",{"claim":752,"sourceUrl":749,"_id":753},"IDPH reviews petitions using expert opinion and the most up-to-date evidence to make decisions that best serve Illinois residents.","6a909933e81f0249cd72d7d6",{"claim":755,"sourceUrl":749,"_id":756},"Illinois currently allows medical cannabis access for more than 50 conditions.","6a909933e81f0249cd72d7d7",{"title":758,"description":759},"Illinois Adds Two Medical Cannabis Qualifying Conditions","Illinois adds sickle cell disease and PMOS with chronic pain to its medical cannabis qualifying conditions list, expanding patient access.",[761],{"name":585,"url":749,"trustTier":39,"_id":762},"6a909933e81f0249cd72d7d4","The Illinois Department of Public Health announced the addition of sickle cell disease and polyendocrine metabolic ovarian syndrome with chronic pain to the state's medical cannabis qualifying conditions list, following a petition review process based on expert opinion and current evidence.","2026-08-28T05:26:14.671Z",{"_id":766,"slug":767,"articleType":121,"body":768,"createdAt":775,"dek":776,"entities":777,"headline":784,"imageAlt":785,"imageUrl":24,"keyFacts":786,"language":33,"publishedAt":72,"seo":803,"sources":806,"summary":809,"updatedAt":810},"6a909948aeddfad21a39f9de","former-massachusetts-cannabis-commission-chair-sues-over-ouster-a5d59f59",[769,770,771,772,773,774],"Former Massachusetts Cannabis Control Commission Chair Shannon O’Brien is suing state Treasurer Deb Goldberg and the commission itself, alleging retaliation and invasion of privacy related to her firing from the position about two years ago.","O’Brien was suspended from the commission in late 2023 and later fired by Goldberg for allegedly making insensitive remarks and contributing to a hostile work environment. She challenged her removal and was ultimately reinstated as commission chair after a judge determined last September that she had been wrongfully terminated.","O’Brien resumed heading the commission in October, was awarded back pay and benefits for being ousted from the position, and served there until Gov. Maura Healey appointed an all-new commission in May.","In the lawsuit, O’Brien claims that Goldberg and the CCC retaliated against her while she was commission chair after she reported actions that she believed were illegal or risky, in violation of the Massachusetts Whistleblower Act. The suit also alleges violations of the Massachusetts Civil Rights Act and that Goldberg invaded her privacy.","A representative from Goldberg’s office said the lawsuit is an attention-seeking effort to revive past-litigated issues. The lawsuit is seeking compensation for damages to be determined by a jury.","Needham attorney Timothy Burke, who filed the suit on O’Brien’s behalf, said O’Brien had suffered economic loss, professional and reputational injury, emotional distress, physical symptoms, litigation expenses, and other compensable damages.","2026-08-27T20:08:40.029Z","Shannon O’Brien alleges retaliation and privacy violations against Treasurer Deb Goldberg and the CCC.",{"brands":778,"products":779,"markets":780,"organizations":782},[],[],[781],"Massachusetts",[783],"Massachusetts Cannabis Control Commission","Former Massachusetts Cannabis Commission Chair Sues Over Ouster","Former Massachusetts Cannabis Control Commission Chair Shannon O’Brien files a lawsuit over her removal from the position.",[787,791,794,797,800],{"claim":788,"sourceUrl":789,"_id":790},"Former Massachusetts Cannabis Control Commission Chair Shannon O’Brien is suing state Treasurer Deb Goldberg and the commission, alleging retaliation and invasion of privacy related to her firing.","https:\u002F\u002Fganjapreneur.com\u002Fformer-massachusetts-cannabis-commission-chair-sues-over-ouster\u002F","6a909948e81f0249cd72d7f5",{"claim":792,"sourceUrl":789,"_id":793},"O’Brien was suspended in late 2023 and later fired by Goldberg for allegedly making insensitive remarks and contributing to a hostile work environment.","6a909948e81f0249cd72d7f6",{"claim":795,"sourceUrl":789,"_id":796},"A judge determined last September that O’Brien had been wrongfully terminated, and she was reinstated as commission chair in October with back pay and benefits.","6a909948e81f0249cd72d7f7",{"claim":798,"sourceUrl":789,"_id":799},"The lawsuit alleges violations of the Massachusetts Whistleblower Act and the Massachusetts Civil Rights Act, and that Goldberg invaded O’Brien’s privacy.","6a909948e81f0249cd72d7f8",{"claim":801,"sourceUrl":789,"_id":802},"The lawsuit seeks compensation for damages to be determined by a jury.","6a909948e81f0249cd72d7f9",{"title":804,"description":805},"Former Massachusetts Cannabis Chair Sues Over Ouster","Shannon O’Brien alleges retaliation and privacy violations against Treasurer Deb Goldberg and the Massachusetts Cannabis Control Commission.",[807],{"name":585,"url":789,"trustTier":39,"_id":808},"6a909948e81f0249cd72d7f4","Former Massachusetts Cannabis Control Commission Chair Shannon O’Brien has filed a lawsuit against state Treasurer Deb Goldberg and the commission, claiming retaliation and invasion of privacy tied to her removal from the position.","2026-08-28T05:26:14.681Z",{"_id":812,"slug":813,"articleType":814,"body":815,"createdAt":821,"dek":822,"entities":823,"headline":830,"imageAlt":831,"imageUrl":24,"keyFacts":832,"language":33,"publishedAt":72,"seo":849,"sources":852,"summary":855,"updatedAt":856},"6a9099c8aeddfad21a39f9df","higher-love-cannabis-co-closes-five-michigan-dispensaries-citing-24-wholesale-tax-e2dc5eef","enforcement",[816,817,818,819,820],"Higher Love Cannabis Co. announced the suspension of operations at five of its nine Michigan dispensaries, with August 9 marking the last day of business at its Upper Peninsula retail locations in Crystal Falls, Escanaba, Houghton, Munising, and Ontonagon.","The company directly tied the closures to Michigan's 24% wholesale tax on cannabis products, describing it as \"another substantial cost in a market already subject to a 10% retail excise tax and 6% sales tax.\"","Higher Love emphasized that while the taxes apply at different supply chain stages and do not combine into a single rate, their collective impact has created an unsustainable operating environment, particularly for compliant businesses serving smaller and rural communities.","The company's retail businesses in Ironwood, Marquette, Menominee, and Norway will remain open. Higher Love noted that the decision comes amid broader industry pressures, including oversupply, price compression, and declining revenue, which have already forced numerous businesses to consolidate or eliminate jobs.","A bill proposed in Michigan in July seeks to repeal the wholesale cannabis tax, but Higher Love did not indicate whether it would restart operations at the closed dispensaries if the bill becomes law.","2026-08-27T20:10:48.488Z","The Upper Peninsula operator suspends retail operations in five towns, blaming the state's wholesale cannabis tax for unsustainable costs.",{"brands":824,"products":826,"markets":827,"organizations":829},[825],"Higher Love Cannabis Co.",[],[828],"Michigan",[],"Higher Love Cannabis Co. Closes Five Michigan Dispensaries, Citing 24% Wholesale Tax","Exterior of a closed Higher Love Cannabis Co. dispensary in Michigan's Upper Peninsula.",[833,837,840,843,846],{"claim":834,"sourceUrl":835,"_id":836},"Higher Love Cannabis Co. closed five of its nine Michigan dispensaries on August 9.","https:\u002F\u002Fganjapreneur.com\u002Fmichigan-cannabis-company-closes-5-dispensaries-due-to-wholesale-cannabis-tax\u002F","6a9099c8e81f0249cd72d83f",{"claim":838,"sourceUrl":835,"_id":839},"The closures affect locations in Crystal Falls, Escanaba, Houghton, Munising, and Ontonagon.","6a9099c8e81f0249cd72d840",{"claim":841,"sourceUrl":835,"_id":842},"The company cited Michigan's 24% wholesale cannabis tax as a key factor in the decision.","6a9099c8e81f0249cd72d841",{"claim":844,"sourceUrl":835,"_id":845},"Higher Love's retail businesses in Ironwood, Marquette, Menominee, and Norway remain open.","6a9099c8e81f0249cd72d842",{"claim":847,"sourceUrl":835,"_id":848},"A bill proposed in Michigan in July seeks to repeal the wholesale cannabis tax.","6a9099c8e81f0249cd72d843",{"title":850,"description":851},"Higher Love Closes 5 Michigan Dispensaries Over Tax","Higher Love Cannabis Co. shut five Upper Peninsula stores, blaming Michigan's 24% wholesale cannabis tax for unsustainable costs.",[853],{"name":585,"url":835,"trustTier":39,"_id":854},"6a9099c8e81f0249cd72d83e","Higher Love Cannabis Co. has closed five of its nine Michigan dispensaries, attributing the decision to the state's 24% wholesale cannabis tax. The closures affect locations in Crystal Falls, Escanaba, Houghton, Munising, and Ontonagon, while four other stores remain open. The company says the tax, combined with other levies and market pressures, has made operations in smaller communities unviable.","2026-08-28T05:26:14.691Z",{"page":858,"limit":859,"total":860,"pages":861},5,18,100,6,{"data":863},{"types":864,"markets":884,"brands":1027,"latestPublishedAt":1135},[865,867,869,871,872,873,876,878,881,882],{"value":121,"count":866},35,{"value":46,"count":868},25,{"value":269,"count":870},9,{"value":548,"count":870},{"value":814,"count":861},{"value":874,"count":875},"licensing",4,{"value":877,"count":875},"finance",{"value":879,"count":880},"brand_launch",3,{"value":8,"count":880},{"value":382,"count":883},2,[885,887,889,892,893,894,895,896,897,898,900,901,902,903,905,906,907,909,910,911,913,914,916,918,920,922,923,925,927,929,931,933,935,937,939,941,943,945,948,950,952,954,956,958,960,962,964,966,968,970,972,974,976,978,980,982,984,986,988,989,991,993,995,996,998,1000,1002,1003,1005,1007,1009,1011,1013,1015,1017,1019,1020,1021,1023,1025],{"value":19,"count":886},19,{"value":179,"count":888},15,{"value":890,"count":891},"California",11,{"value":178,"count":891},{"value":287,"count":870},{"value":828,"count":861},{"value":561,"count":861},{"value":653,"count":861},{"value":133,"count":861},{"value":899,"count":875},"New York",{"value":462,"count":875},{"value":183,"count":875},{"value":288,"count":880},{"value":904,"count":880},"Texas",{"value":781,"count":880},{"value":181,"count":880},{"value":908,"count":880},"Montana",{"value":180,"count":880},{"value":182,"count":880},{"value":912,"count":880},"Washington",{"value":702,"count":883},{"value":915,"count":883},"Minnesota",{"value":917,"count":883},"Nebraska",{"value":919,"count":883},"Thailand",{"value":921,"count":883},"Europe",{"value":95,"count":883},{"value":924,"count":883},"Pennsylvania",{"value":926,"count":883},"Kentucky",{"value":928,"count":883},"Alabama",{"value":930,"count":883},"Maryland",{"value":932,"count":883},"Washington State",{"value":934,"count":883},"Delaware",{"value":936,"count":883},"Virginia",{"value":938,"count":883},"US federal",{"value":940,"count":883},"Maine",{"value":942,"count":883},"Rhode Island",{"value":944,"count":883},"North Carolina",{"value":946,"count":947},"Brazil",1,{"value":949,"count":947},"hemp market",{"value":951,"count":947},"TSX",{"value":953,"count":947},"Argentina",{"value":955,"count":947},"NASDAQ",{"value":957,"count":947},"New Hampshire",{"value":959,"count":947},"New Jersey",{"value":961,"count":947},"Missouri",{"value":963,"count":947},"North America",{"value":965,"count":947},"Houston",{"value":967,"count":947},"Indiana",{"value":969,"count":947},"Mississippi",{"value":971,"count":947},"hemp",{"value":973,"count":947},"Wyoming",{"value":975,"count":947},"Global",{"value":977,"count":947},"Georgia",{"value":979,"count":947},"Colombia",{"value":981,"count":947},"retail cannabis",{"value":983,"count":947},"Chile",{"value":985,"count":947},"CA",{"value":987,"count":947},"Florida",{"value":512,"count":947},{"value":990,"count":947},"Washington, D.C.",{"value":992,"count":947},"India",{"value":994,"count":947},"Utah",{"value":57,"count":947},{"value":997,"count":947},"cannabis",{"value":999,"count":947},"OTCQX",{"value":1001,"count":947},"Wisconsin",{"value":404,"count":947},{"value":1004,"count":947},"CBD",{"value":1006,"count":947},"San Francisco",{"value":1008,"count":947},"Oklahoma",{"value":1010,"count":947},"Humboldt County, California",{"value":1012,"count":947},"Latin America",{"value":1014,"count":947},"EU",{"value":1016,"count":947},"Sacramento, California",{"value":1018,"count":947},"Oregon",{"value":461,"count":947},{"value":603,"count":947},{"value":1022,"count":947},"District of Columbia",{"value":1024,"count":947},"New Mexico",{"value":1026,"count":947},"BC",[1028,1029,1030,1031,1033,1034,1036,1038,1039,1041,1043,1045,1047,1049,1051,1053,1055,1057,1059,1060,1062,1064,1065,1066,1068,1069,1071,1073,1075,1077,1079,1081,1082,1084,1085,1087,1088,1090,1092,1094,1096,1098,1100,1101,1102,1103,1104,1106,1107,1109,1111,1112,1113,1115,1116,1118,1120,1122,1124,1126,1128,1130,1132,1134],{"value":282,"count":861},{"value":338,"count":875},{"value":283,"count":883},{"value":1032,"count":883},"Target",{"value":284,"count":883},{"value":1035,"count":947},"Cannabis Europa",{"value":1037,"count":947},"Rx Green Technologies",{"value":396,"count":947},{"value":1040,"count":947},"Cresco",{"value":1042,"count":947},"ABC Fine Wine & Spirits",{"value":1044,"count":947},"Curaleaf Inc.",{"value":1046,"count":947},"Callie's Apothecary",{"value":1048,"count":947},"Ascend Wellness Holdings Inc.",{"value":1050,"count":947},"BevMo! by Gopuff",{"value":1052,"count":947},"BamaBloom",{"value":1054,"count":947},"Gramz",{"value":1056,"count":947},"Sunnyside",{"value":1058,"count":947},"Green Thumb Industries",{"value":342,"count":947},{"value":1061,"count":947},"Total Wine & More",{"value":1063,"count":947},"Beast Media",{"value":186,"count":947},{"value":172,"count":947},{"value":1067,"count":947},"High Rollers",{"value":233,"count":947},{"value":1070,"count":947},"Team Winston",{"value":1072,"count":947},"Storz & Bickel",{"value":1074,"count":947},"AYR Wellness Inc.",{"value":1076,"count":947},"Wana Brands",{"value":1078,"count":947},"Square",{"value":1080,"count":947},"R'belle",{"value":698,"count":947},{"value":1083,"count":947},"Verano Holdings LLC",{"value":171,"count":947},{"value":1086,"count":947},"Mind Forward",{"value":699,"count":947},{"value":1089,"count":947},"iAnthus",{"value":1091,"count":947},"Lotus Farmacy",{"value":1093,"count":947},"Blunt Brunch",{"value":1095,"count":947},"Lovewell Farms",{"value":1097,"count":947},"PPX",{"value":1099,"count":947},"Tweed",{"value":232,"count":947},{"value":508,"count":947},{"value":650,"count":947},{"value":397,"count":947},{"value":1105,"count":947},"Spec's Wine and Spirits & Finer Foods",{"value":825,"count":947},{"value":1108,"count":947},"Aery Group",{"value":1110,"count":947},"The Woods",{"value":173,"count":947},{"value":231,"count":947},{"value":1114,"count":947},"Blue Sage",{"value":697,"count":947},{"value":1117,"count":947},"Claybourne",{"value":1119,"count":947},"Jetty",{"value":1121,"count":947},"Trulieve Inc.",{"value":1123,"count":947},"Cova Software",{"value":1125,"count":947},"EmpowHer Cannabis Society",{"value":1127,"count":947},"Decibel Cannabis",{"value":1129,"count":947},"Trulieve",{"value":1131,"count":947},"HiWay",{"value":1133,"count":947},"Cannabis Health",{"value":395,"count":947},"2026-09-17T18:05:05.641Z"]